word count: 196 2 Text word count: 4470 3 ABSTRACT Adult T-cell leukemia (ATL) is a highly aggressive T-cell malignancy induced by human T-cell leukemia virus type 1 (HTLV-1) infection. Long noncoding RNA (lncRNA) plays a critical role in the development and progression of multiple human cancers. However, the function of lncRNA on HTLV-1-induced oncogenesis has not been elucidated. In the present study, we show that the expression of the lncRNA ANRIL was elevated in HTLV-1 infected cell lines and clinical ATL samples. E2F1 induced ANRIL transcription by enhancing its promoter activity. Knocking down of ANRIL in ATL cells repressed cellular proliferation and increased apoptosis in vitro and in vivo.
INTRODUCTION
Human T-cell leukemia virus type 1 (HTLV-1) is a retrovirus that transforms human T lymphocytes (1) . After a long latency period, about 2-5% of individuals infected with HTLV-1 develop adult T-cell leukemia (ATL) (1) . HTLV-1 encodes several regulatory (tax and rex) and accessory (p12, p13, p30, and HBZ) genes in the pX region located between the env and 3' long terminal repeat (LTR) (1) . Among all of the HTLV transcripts, the tax gene is thought to play critical role in leukemogenesis because of its pleiotropic functions (2) . Tax activates transcriptional pathways, including nuclear factor-κB (NF-κB), cAMP response element-binding protein (CREB), activator protein-1 (AP-1), and serum responsive factor (SRF) (2) . The constitutive activation of the NF-κB pathway in HTLV-1 transformed T-cells argues for a critical role of this factor in mediating the development of ATL (3) . However, Tax-mediated NF-κB activation may not fully explain ATL biology, because some leukemic cells that no longer express Tax continue to show constitutive NF-κB activation (4, 5) . Recent reports provide new evidence that elevated expression of NF-κB-inducing kinase (NIK) has a pivotal role in the activation of the alternative NF-κB pathway in ATL independent of Tax expression (6) . However, it remains unknown whether other mechanisms underlying the Tax-independent activation of the NF-κB pathway are involved in the development of ATL.
Regulatory noncoding RNAs (ncRNAs), such as microRNAs, small interfering RNAs, and long noncoding RNAs (lncRNAs), play important roles in the development 6 of human diseases (7) . LncRNAs, ranging from 200 to 100,000 nucleotides, are involved in a range of biologic processes, including modulation of cell growth, apoptosis, stem cell pluripotency, and immune response through the modulation of gene expression by epigenetic regulation, chromatin remodeling, transcription, and posttranscriptional processing (8, 9) . Additionally, accumulating evidence has shown that lncRNAs play a critical role in tumorigenesis (10) . However, the contribution by lncRNAs to the genesis of HTLV-1 induced ATL has not been investigated.
Recently, lncRNA ANRIL (antisense noncoding RNA in the INK4 locus), which is transcribed from the INK4b-ARF-INK4a gene cluster in the opposite direction, has been identified as a genetic susceptibility locus associated with human disease, in particular cancers (11) (12) (13) . ANRIL was involved in repression of the p15/CDKN2B-p16/CDKN2A-p14/ARF gene cluster in Cis by directly binding to the polycomb repressor complex 2 (PRC2), which resulted in increased cell proliferation and suppression of apoptosis (14) (15) (16) .
PRC2 has been demonstrated to be a functional target of some lncRNA, e.g., ANRIL, HOTAIR, Fendrr, H19, MALAT1, and COLDAIR (14, 15, (17) (18) (19) (20) (21) . Moreover, PRC2/lncRNA complex-mediated dynamic control of H3K27 trimethylation (H3K27me3) is central to gene silencing in various cellular processes (8, 22) . Enhancer of zeste homolog 2 (EZH2), one of the genes identified to be aberrantly overexpressed in ATL, is a component of PRC2. EZH2 contains a catalytic domain (SET domain) at the COOH-terminus that provides the methyltransferase activity, which plays a key role in the epigenetic maintenance of repressive chromatin marks (23, 24) . In addition to its 7 known role as transcriptional suppressor, several studies have also identified a PRC2-independent function of EZH2 in transcriptional activation rather than repression (25) (26) (27) (28) . In castration-resistant prostate cancer, EZH2 acts as a co-activator for critical transcription factors including the androgen receptor (AR) (29) . This functional switch is dependent on phosphorylation of EZH2, and requires an intact methyltransferase domain. The activation role of EZH2 was also demonstrated in breast cancer cells, in which EZH2 activates NF-κB targets or NOTCH1 (27, 28) . However, the significance and potential role of polycomb group proteins and the associated lncRNA in ATL is still unknown.
In this study, we report that ANRIL interacted with EZH2 to support proliferation of ATL cells, indicating that dysregulation of the ANRIL is associated with the leukemogenesis of ATL.
RESULTS

LncRNA ANRIL is up-regulated in ATL
LncRNAs have been reported to be associated with the development of various cancers (7, 14, 19, 20) . To identify lncRNAs that are involved in the development of ATL, we first examined the expression of selected onco-lncRNAs in HTLV-1-infected cell lines. Compared with HTLV-1 noninfected control cells, the level of ANRIL, H19, and SAF was enhanced in ATL cells, whereas three lncRNAs were found to be either slightly reduced (HOTAIR and TUSC7) or unchanged (MALAT1) in expression ( Fig.   S1 ). Since ANRIL was more highly expressed in ATL cells, our subsequent studies focused on ANRIL. The real-time PCR results verified the enhanced expression of ANRIL in HTLV-1-infected cell lines ( Fig. 1A ). Next, we examined the expression of ANRIL in primary ATL cells isolated from patients in comparison with PBMCs from healthy subjects under resting conditions. Primary ATL cells expressed ANRIL at levels much higher than healthy PBMCs (Fig. 1B) .
E2F1 induces ARNIL expression in T cells
To investigate the mechanism of up-regulation of ANRIL in ATL cells, we amplified the putative promoter region of ANRIL (encompassing the -851 to +29 region), and cloned it into a pGL3-Basic reporter plasmid. Next, we searched for possible transcription factor binding sites in the promoter region using TESS (Transcription Element Search Software). E2F1, Sp1, and CTCF binding sites were found in this region. Reporter 9 assay was performed to explore whether the putative transcription factors could affect ANRIL promoter activity. As shown in Fig. 1C , overexpression of E2F1 led to an increase of ANRIL (-851/+29)-luciferase expression, whereas Sp1 and CTCF had no effect. To investigate whether E2F1 indeed altered ANRIL expression in T cells, we over-expressed E2F1 in Jurkat cells. The results showed that enforced expression of E2F1 markedly upregulated the level of the ANRIL gene transcript (Fig. 1D ). ChIP assays verified the binding of E2F1 to the promoter region of ANRIL in multiple ATL cell lines ( Fig. 1E ). These results collectively indicate that the enhanced expression of ANRIL in ATL can be attributed to the association of E2F1 with the ANRIL promoter.
Knockdown of ANRIL impairs cellular proliferation and induces apoptosis in vitro
To clarify the potential role of upregulated ANRIL expression in ATL cells, we knocked down ANRIL by short hairpin RNA (shRNA) in HPB-ATL-T and ED cells. Two lentivirally expressed shRNAs directed against ANRIL resulted in a reduction of ANRIL expression compared with the vector control ( Fig. 2A and B ). MTT assays revealed that reduction of ANRIL expression significantly inhibited cell proliferation both in HPB-ATL-T and ED cell lines ( Fig. 2C and D) . In fact, ANRIL knockdown resulted in a 3-4 fold decrease in clonogenic survival of HPB-ATL-T cells ( Fig. 2E ).
shANRIL#2 induced less-efficient knockdown of ANRIL than shANRIL#1, resulting in less inhibition of cell proliferation. In addition, ANRIL knockdown increased the total number of apoptotic cells in both the HPB-ATL-T and ED cell lines ( Fig. 2F ).
Next, we evaluated if the effect of knockdown of ANRIL on ATL cell proliferation 10 was due to cell cycle arrest. Flow cytometry results indicated that the proportion of cells in G1/S phase increased in ANRIL knockdown cells compared with the corresponding control. This suggested that reduction of ANRIL expression blocked cell cycle progression ( Fig. S2 ).
Taken together, these observations demonstrate that ANRIL silencing suppressed proliferation of ATL cells, and this inhibitory effect was partially due to the inhibition of cell cycle progression and the promotion of apoptosis.
ANRIL promotes proliferation of ATL cells in vivo
To further investigate the ability of ANRIL to stimulate ATL tumorigenesis in vivo, we injected an equivalent number of ED negative control and ED ANRIL knockdown cells into NCG mice and analyzed tumor growth. The tumors formed by ED-shANRIL#1 were smaller in both size and weight compared to ED-control tumors (Fig. 3A , B and C). Real-time PCR revealed that tumor nodules originating from ED-shANRIL#1 cells had decreased ANRIL, MYC, VCAM1, CDK6, and CCND1 genes, and increased CDKN1A and CTGF expression compared to nodules originating from ED-control cells ( Fig. 3D ). H&E staining of the tumors showed that the degree of cell differentiation was significantly higher in ANRIL knockdown derived tumors compared to the control tumors ( Fig. 3E ).
Overall, these results confirm our in vitro transformation assays and suggest that ANRIL has tumor-forming potential.
ANRIL and EZH2 synergistically activate the NF-κB pathway
Interestingly, as shown in Fig. 3D , the genes that were differentially expressed upon ANRIL depletion are many well-known NF-κB target genes, such as MYC, VCAM1, CDK6, and CCND1. Therefore, we evaluated whether ANRIL could influence the NF-κB pathway in ATL. As shown in Fig It is well established that lncRNA may achieve regulatory goals through interacting with protein partners, and modulating the activity of these proteins within the cell. EZH2, which is a functional target of some lncRNAs, was constitutively expressed in all HTLV-1-infected cell lines and primary ATL cells ( Fig. S3A and B ). The association between ANRIL and EZH2 was confirmed to occur endogenously in an ATL cell line, HPB-ATL-T ( Fig. 4C ). Consistent with a previous report (27) , EZH2 enhanced p65-induced NF-κB activation ( Fig. S3C ). Furthermore, in the presence of ANRIL, p65/EZH2-mediated NF-κB activation was dramatically reinforced, whereas it had a less obvious effect without EZH2 ( Fig. 4D ). To confirm the synergistic effect of ANRIL and EZH2 on NF-κB activation, we measured κB-Luciferase activity after suppressing EZH2 expression in ANRIL-silenced cells. Treatment with DZNep, an EZH2 inhibitor, further suppressed NF-κB signaling in ANRIL knockdown cells, indicating that ANRIL and EZH2 could cooperatively activate NF-κB pathway ( Fig. 4E ).
Next, we detected whether p65 was required for the ANRIL-enhanced cell proliferation of ATL cells. MTT assay showed that the decreased cell proliferation ability by shANRIL was partially rescued by p65 ( Fig. 4F ). These results together suggest that ANRIL supports proliferation of ATL cells through activating NF-κB pathway via EZH2.
ANRIL associates with EZH2 and p65, and enhances NF-κB signaling independent of HMT activity
To clarify the mechanism by which ANRIL/EZH2 enhances NF-κB transcriptional response, FLAG-tagged p65 and myc-tagged EZH2 were cotransfected into 293FT cells.
An interaction of EZH2 with p65 was demonstrated ( Fig. 5A ). Furthermore, ANRIL greatly enhanced the interaction between EZH2 and p65 ( Fig. 5B ). As ANRIL enhanced the activation of NF-κB signaling by EZH2 and p65, we explored whether ANRIL could form a complex with EZH2 and p65. 293FT cells were transfected with vectors expressing ANRIL, Myc-EZH2, and FLAG-p65, and a serial RNA immunoprecipitation assay was performed. As shown in Fig. 5C , we detected a specific ternary complex only when the three components were coexpressed. To investigate the binding of EZH2/ANRIL/p65 to DNA, we performed a ChIP assay in 293FT cells that were cotransfected with an κB-Luc reporter along with expression vectors for EZH2, ANRIL, and p65. The ChIP assay showed that EZH2 and ANRIL dramatically enhanced p65 13 DNA binding capability ( Fig. 5D ). Moreover, interaction of p65 to NF-κB binding site was diminished in ATL-T cells silencing both ANRIL and EZH2 (Fig. 5E ). These results together suggest that ANRIL augments the interaction between EZH2 and p65, thereby potentiating NF-κB signaling.
We next evaluated the ANRIL deletion mutants shown in Fig. 5F to determine which region of ANRIL is responsible for activating NF-κB signaling. Luciferase experiments revealed that the only full-length ANRIL could reinforced EZH2/p65-mediated NF-κB activation, whereas the truncated lncRNAs could not, suggesting that the tertiary structure of the full length of ANRIL, rather than one or more ANRIL domains was responsible for potentiating NF-κB signaling (Fig. 5F ).
Accumulating evidence shows that the EZH2 SET domain, which has histone methyltransferase activity, is required to induce gene silencing by interacting with ANRIL (15, 21, 23, 24) . We asked whether the HMT catalytic function of EZH2 is required for ANRIL/EZH2 complex to positively regulate NF-κB-dependent transcription in ATL cells. We first compared the EZH2 and EZH2 SET domain deletion mutant (EZH2-∆SET) for the ability to activate the NF-κB pathway. As shown in Fig.   5G , lentiviral overexpression of EZH2-∆SET resulted in a robust induction of NF-κB reporter activity, which was comparable to that of EZH2 wild type. In co-IP experiments in 293FT cells transfected with myc-tagged EZH2 or EZH2-∆SET, we detected p65 in both EZH2 and EZH2-∆SET immunoprecipitates (Fig. 5H ). In addition, co-IP experiments revealed that ANRIL/EZH2 complex interacted with the Rel homology domain of p65 ( Fig. 5I ).
Taken all together, these data indicate that the complex of ANRIL/EZH2/p65 enhances NF-κB pathway in a histone methyltransferase activity independent manner.
ANRIL/EZH2 suppresses p21/CDKN1A expression by histone methylation dependent mechanism
We next examined whether ANRIL support proliferation of ATL cells through modulating the expression of genes involved in apoptosis and proliferation. Cleaved caspase-3, caspase-7, and PARP were increased in HPB-ATL-T and ED cells with transfection of shANRIL ( Fig. S4 ). Consistent with the results of the flow cytometry assay, in which knockdown of ANRIL induced cell cycle arrest, cyclin D1 and cyclin E1 expression was decreased in ANRIL knockdown HPB-ATL-T and ED cells ( Fig. S4 ).
Several reports have indicated that ANRIL suppressed the expression of the p15/CDKN2B-p16/CDKN2A-p14/ARF gene cluster and contributed to cancer cell proliferation (14) (15) (16) . However in the present study, there was no significant difference in the expression of p15/CDKN2B or p16/CDKN2A in ANRIL knockdown cells compared with control cells (Fig. 6A ). Consistent with the observations in vivo, we did find that knockdown of the ANRIL gene led to increased p21/CDKN1A expression, indicating that p21/CDKN1A could be ANRIL novel targets in ATL ( Fig. 6A ).
It was previously reported that p21/CDKN1A was down regulated in ATL due to methylation of its promoter region (33) . We next investigated if ANRIL could also affect the expression of p21/CDKN1A by histone methylation. After treatment with the EZH2 inhibitor DZNep, the mRNA and protein levels of p21/CDKN1A were increased in 15 HPB-ATL-T cells (Fig. 6B) . The results of a ChIP assay showed that overexpression of EZH2 resulted in the accumulation of H3K27 trimethylation on the promoter of p21/CDKN1A, which was further enhanced by ANRIL (Fig. 6C ).
In order to evaluate the contribution of p21/CDKN1A to ANRIL-induced ATL cell proliferation, we performed a rescue experiment. As shown in Fig. 6D , down regulation of p21/CDKN1A in ANRIL silenced cells partially rescued shANRIL impaired proliferation of HPB-ATL-2 cells. These results suggest that ANRIL/EZH2 supports proliferation of ATL cells through inhibiting the expression of p21/CDKN1A via histone methylation dependent mechanism.
Collectively, these data support a model in which ANRIL/EZH2 complex not only contributes to the activation of NF-κB signaling, but also mediates transcriptional silencing of p21/CDKN1A in ATL. Moreover, we propose that the molecular mechanism through which ANRIL/EZH2 supports proliferation of ATL cells involves both histone methylation dependent and independent mechanisms ( Fig. 7 ).
DISCUSSION
The NF-κB signaling pathway, constitutively activated in a variety of cancers, plays a major role in tumor biology as a regulator of key processes of cancer initiation and progression (34) . In ATL, Tax-mediated NF-κB activation is reported to be critical for the proliferation of ATL cells and for the transforming activity of HTLV-1 (35) . However, ATL cells from most new cases, although infected with HTLV-1, are characterized by a loss of the expression of viral proteins, including Tax, because of host immune surveillance during the long latent period of the virus (1) . The fact that NF-κB signaling is strongly and persistently activated in ATL cells implicates other viral and/or cellular factors. It has been reported that NIK may replace Tax in maintaining the constitutive activation of NF-κB, and NIK has been implicated in ATL pathogenesis (6) . However, NIK does not seem to be essential for NF-κB activation in all ATL cells, as nuclear NF-κB was not exclusively expressed in NIK-overexpressing cell lines (6) . EZH2, a histone methyltransferase subunit of a polycomb repressor complex, is highly expressed in a wide range of neoplasms, including cancers of the breast, lung, and pancreas, sarcomas, and lymphomas (36) . The extensive evidence linking EZH2 activity to cancer has prompted interest in the underlying mechanism. We present evidence that EZH2 and its associated lncRNA ANRIL are highly expressed in ATL. EZH2 activated the NF-κB pathway in ATL cells through physical interaction with ANRIL and RelA (p65), and this positive regulation of NF-κB signaling did not require its methyltransferase activity.
This constitutive activation by EZH2/ANRIL/RelA complex may explain how NF-κB is activated in the absence of Tax, and advances our understanding of how EZH2 may function as an oncogene. Consistent with our findings, it was recently reported that hepatitis B virus (HBV) infection induces EpCAM expression via RelA in complex with EZH2, and EZH2/RelA complex acts as an activator of NOTCH1 signaling to accelerate breast cancer growth, supporting that recruitment of RelA is essential for the oncogenic function of EZH2 (28, 37) .
Over-expression of an active form of EZH2 was demonstrated in ATL cells (38) .
Further study showed that the over-expressed EZH2 exhibited histone methyltransferase activity, as the ATL cells were strongly positive for H3K27me3 (39) . The EZH2-mediated global methylation gain at H3K27 caused silencing of tumor suppressors, transcription factors, and miRNAs, supporting leukemic cell characteristics.
In addition to its known roles in histone modification and transcriptional regulation, EZH2 also promotes tumorigenicity of various cancers independent of its H3K27 methyltransferase activity, and of the polycomb repressive complex 2, through transcriptional activation marks (25) (26) (27) (28) . Our study defines a unique role and mechanism for EZH2 in ATL, whereby EZH2 utilizes polycomb-dependent and -independent mechanisms to protect ATL cells from apoptosis and promote their proliferation.
Recently, Yamagishi et al. reported that overexpression of EZH2 led to polycomb-mediated silencing of miR-31 and constitutive activation of NF-κB signaling (40) . Our results complement this finding and highlight a novel mechanism for NF-κB activation in ATL, where an aberrant overexpression of EZH2 activates NF-κB through both HMT-dependent and -independent pathways. In addition, because EZH2 18 was undetectable in cells from healthy adults and HTLV-1 carriers, it is likely that deregulation of NF-κB caused by EZH2 is involved in the early steps of ATL oncogenesis. Association between EZH2 and RelA are essential for NF-κB activation, whereas the epigenetic modification function of EZH2 requires the recruitment of PRC2 subunits, such as SUZ12 and EED. Thus, we speculate that the bimodal function of the EZH2-ANRIL complex depends on the EZH2 binding partner. Global changes in the epigenetic landscape are a hallmark of cancer (45) . Since genetic changes in specific genes in ATL cells have not been identified except for p53 and p16, and there is no consistent chromosomal change, it is possible that epigenetic changes such as DNA methylation, histone modification, and ncRNAs, which dysregulate transcription of oncogenes, play an important role in oncogenesis (46) . In ATL cells, DNA methylation of the promoter regions of tumor suppressor genes (p21 and p16, etc.) and of the 5'LTR of HTLV-1 is commonly observed and accumulates with disease progression (1, 33, 47) . A recent study showed that PRC2-mediated trimethylation at H3K27 (H3K27me3) was significantly and frequently reprogrammed at half of genes in ATL cells (39) . In this study, we identify a novel mechanism of down regulation of p21/CDKN1A due to EZH2/ANRIL triggered histone H3K27 promoter trimethylation. It has recently become apparent that DNA methylation and histone modification pathways can be dependent on one another (48) . Moreover, EZH2 controls CpG methylation through direct physical contact with DNA methyltransferases (49) . It is thus likely that, apart from its regulatory function on p16/CDKN1A expression, EZH2 may dysregulate transcription of other tumor suppresser genes in ATL cells by two dependent epigenetic means to acquire malignant phenotypes. However, it remains unknown how EZH2 selectively regulates its target genes by DNA methylation or histone modification. We speculate that the regulatory effect of EZH2 on its target gene expression is dependent on its affinity to DNA, and may also depend on its associating 20 transcription factors. Further studies are needed to fully elucidate the role of EZH2/ANRIL in HTLV-1 infection and ATL.
In summary, we showed that ANRIL supported the proliferation of ATL cells by interacting with EZH2. HTLV-1 may take advantage of these mechanisms to allow the infected cells to proliferate in vivo. These findings may contribute to the development of novel therapeutic strategies. 
MATERIALS AND METHODS
Cell culture and clinical samples
Plasmids and reagents
The sequence of ANRIL was amplified by reverse transcriptase-polymerase chain reaction (RT-PCR) and subcloned into pCSII-CMV-GFP. The ANRIL promoter sequence was cloned into pGL3-Basic vector (pGL3-ANRIL -851/+29). Expression vectors for E2F1, Sp1, Tax, p65, p65 deletion mutants, CTCF, κB-Luc, and phRL-TK were prepared as previously described (30, 31 USA). Semiquantitative RT-PCR was performed as previously described (30) . The specific primers used can be found in Table S2 .
Luciferase assay
Jurkat cells were plated on 12-well plates at 1.2×10 5 cells per well. After 24 hours, cells were transfected with the indicated plasmids using Lipofectamin LTX Reagent (Invitrogen). At 48 hours after transfection, a luciferase reporter assay was performed using the Dual-Luciferase Reporter Assay System (Promega, Madison, WI). Each experiment was performed in triplicate, and the data represent the mean and SD of 3 independent experiments, each normalized to Renilla activity.
Chromatin immunoprecipitation assay
293FT cells were transfected with the indicated plasmids. At 48 hours after transfection, a ChIP assay was done according to the protocol recommended by Upstate Biotechnology. Precipitated DNA was amplified by PCR using primers specific for the ANRIL-Luc, κB-Luc, or p21/CDKN1A promoter vectors respectively. For the endogenous ANRIL promoter, chromatin samples prepared from ATL-T cells were subjected to ChIP analysis using anti-E2F1 (Abcam, Cambridge, MA) and normal mouse immunoglobulin G (Santa Cruz Biotechnology). Sequences for the primer set can be found in Table S2 .
Knockdown
Knockdown of ANRIL and p21/CDKN1A in ATL cell lines was performed with a lentiviral vector pLKO.1-based shRNA system (Open Biosystems, Lafayette, CO, USA) (31) . Stable transfectants were selected in puromycin. The shRNA sequence specifically targeting ANRIL and CDKN1A was shANRIL #1:
5'-GGAATGAGGAGCACAGTGA-3', shANRIL #2:
5'-AAGCGAGGTCATCTCATTGCTCTAT-3', shCDKN1A:
5'-GCGATGGAACTTCGACTTT-3'.
Cell proliferation assay
Cells were seeded in 96-well plates and at indicated time points, 10 µl of 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide solution was added. Cells were incubated at 37 °C for 2 h and then lysed by 100 µl of lysis buffer (4% Triton X-100 and 0.14% HCl in 2-propanol). Absorbance at 595nm was measured on a Microplate Reader (Bio-Rad, Hercules, CA).
Colony formation assay
Stable knockdown cells were plated on 6-well plates at 1000 cells per well, and kept in complete medium for 2 weeks. Colonies were fixed with methanol and stained with methylene blue. Colony formation was determined by counting the number of stained colonies. Triplicate wells were measured in each group.
Measurement of apoptotic cell death
Apoptotic cells were routinely identified by Annexin V (Biolegend, San Diego, CA), 
In vivo tumorigenicity assay
Cell suspensions (4×10 6 cells) was injected subcutaneously into the right flank of female NCG mice (NOD-Prkdc em26Cd52 Il2rg em26Cd22 /Nju, NOD/ShiLtJNju based immune deficient mice) (Model Animal Research Center of Nanjing University, China). Thirty days after injection, all mice were killed. Tumors weight and the expression of ANRIL RNA and its target genes were measured. All animals used in this study were maintained and handled according to protocols approved by Zhejiang Normal
25
University and Huaqiao University.
Histological analyses
Tissue samples were fixed in 10% formalin in phosphate buffer and then embedded in paraffin. Haematoxylin and eosin (H&E) staining was performed according to standard procedures. Images were captured using confocal laser scanning microscope (Leica TCS SP5 AOBS). 
Immunoprecipitation (IP) and immunoblotting
RNA immunoprecipitation
RNA immunoprecipitation was performed using a MagnaRIP RNA-binding protein 26 immunoprecipitation kit (Millipore) according to the manufacturer's instructions. For sequential RNA immunoprecipitation, transfected 293FT cells were lysed in radioimmunoprecipitation assay buffer and immunoprecipitated with anti-FLAG M2 agarose affinity gel. The precipitates were eluted with FLAG peptide and the eluate diluted with radioimmunoprecipitation assay buffer, immunoprecipitated with anti-Myc antibody, and co-precipitated RNAs were detected by PCR. The EZH2 antibody used for RNA immunoprecipitation was purchased from Cell Signaling Technology. The primers used to detect ANRIL expression can be found in Table S2 .
Statistical analyses
Statistical analyses were performed using the unpaired Student t test. Significance was set at alpha = 0.05. 
